Cough in Idiopathic Pulmonary fibrosis.
Conditions
Interventions
Trade Name: Thalidomide Pharmion
Product Name: Thalidomide Pharmion
Pharmaceutical Form: Capsule
Trade Name: PREDNISOLONE
Product Name: prednisolone
Pharmaceutical Form: Tablet
Sponsors
University of Nottingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Diagnosis of Pulmonary Fibrosis (including idiopathic, hypersensitivity, non specific Interstitial pneumonitis) as per International consensus/ guidelines. 2.Cough 3.Age>50/ Non child bearing potential Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Clinical Reflux Subclinical reflux Unable to give informed consent Women of childbearing age Peripheral neuropathy Risk for TED including: Major co-morbidity including medication known to interact with thalidomide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: We want to explore the effect of Thalidomide on sputum and blood biomarkers in IPF cough.;Secondary Objective: To measure cough and assess if thalidomide improves it. ;Primary end point(s): The difference in biomarker in sputum and blood at beginning and end of study. | — |
Countries
United Kingdom
Outcome results
None listed